Charles Schwab Investment Management Inc. Decreases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Charles Schwab Investment Management Inc. cut its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 1.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,122,733 shares of the biopharmaceutical company’s stock after selling 14,840 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Dynavax Technologies were worth $12,507,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares during the period. US Bancorp DE lifted its position in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of Dynavax Technologies in the third quarter worth $45,000. Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Algert Global LLC bought a new position in shares of Dynavax Technologies in the second quarter worth approximately $140,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Trading Up 0.2 %

Shares of DVAX opened at $12.85 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a 50 day simple moving average of $11.85 and a two-hundred day simple moving average of $11.44. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The firm has a market cap of $1.69 billion, a P/E ratio of 98.85 and a beta of 1.33.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.